Breathlessness (dyspnoea) at 1 week (intensity) Scale 0–10; lower score = less breathlessness · adults with cancer‐related breathlessness (dyspnoea)
1 finding from 1 review
Dyspnea · adults with cancer‐related breathlessness (dyspnoea)
2 findings from 1 review
Adverse events · adults with cancer‐related breathlessness (dyspnoea)
1 finding from 1 review
Patient satisfaction with treatment · adults with cancer‐related breathlessness (dyspnoea)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals (parallel group trials/first arm cross‐over trials) · adults with cancer‐related breathlessness (dyspnoea)
1 finding from 1 review
Day 5 · children with acute otitis media
1 finding from 1 review
Day 14 · children with acute otitis media
1 finding from 1 review
Reduction in overall or specific symptom duration · children with acute otitis media
1 finding from 1 review
Adverse effects · children with acute otitis media
1 finding from 1 review
Death at final · primary membranous nephropathy in adults with nephrotic syndrome
Oral alkylating agents ± steroids showed no clear difference in death at final compared with placebo/no treatment/steroids (low certainty).
1 finding from 1 review
End‐stage renal disease · primary membranous nephropathy in adults with nephrotic syndrome
Oral alkylating agents ± steroids probably leads to lower end‐stage kidney disease at final compared with placebo/no treatment/steroids (moderate certainty).
1 finding from 1 review
Total remission (complete or partial) at final · primary membranous nephropathy in adults with nephrotic syndrome
Oral alkylating agents ± steroids probably leads to higher total remission (complete or partial) at final compared with placebo/no treatment/steroids (moderate certainty).
1 finding from 1 review
Complete remission · primary membranous nephropathy in adults with nephrotic syndrome
Oral alkylating agents ± steroids probably leads to higher complete remission at final compared with placebo/no treatment/steroids (moderate certainty).
1 finding from 1 review
Relapse · primary membranous nephropathy in adults with nephrotic syndrome
It is very uncertain whether oral alkylating agents ± steroids changes recurrence of disease (relapse) at final compared with placebo/no treatment/steroids (very low certainty).
1 finding from 1 review
100% increase in SCr at final · primary membranous nephropathy in adults with nephrotic syndrome
Oral alkylating agents ± steroids showed no clear difference in 100% increase in serum creatinine at final compared with placebo/no treatment/steroids (moderate certainty).
1 finding from 1 review
Adverse events ‐ temporary or permanent discontinuation/hospitalisation at final · primary membranous nephropathy in adults with nephrotic syndrome
Oral alkylating agents ± steroids may leads to higher adverse events ‐ temporary/permanent discontinuation or… compared with placebo/no treatment/steroids (low certainty).
1 finding from 1 review
Adverse events ‐ infection at 3 years · primary membranous nephropathy in adults with nephrotic syndrome
It is very uncertain whether oral alkylating agents ± steroids changes adverse events ‐ infection at 3 years compared with placebo/no treatment/steroids (very low certainty).
1 finding from 1 review
Adverse events: malignancy · primary membranous nephropathy in adults with nephrotic syndrome
It is very uncertain whether oral alkylating agents ± steroids changes adverse events ‐ malignancy at final compared with placebo/no treatment/steroids (very low certainty).
1 finding from 1 review
Death at final · primary membranous nephropathy in adults with nephrotic syndrome
It is very uncertain whether calcineurin inhibitors ± steroids changes death at final compared with placebo/no treatment/supportive treatment/steroids (very low certainty).
1 finding from 1 review
End‐stage renal disease · primary membranous nephropathy in adults with nephrotic syndrome
It is very uncertain whether calcineurin inhibitors ± steroids changes end‐stage kidney disease at final compared with placebo/no treatment/supportive treatment/steroids (very low certainty).
1 finding from 1 review